相似文献/References:
[1]朱莉莎,颜建周,张伶俐,等.英国、比利时罕用药医保准入机制及其对我国的启示[J].卫生经济研究,2016,(08):48.
[2]邵 蓉,孙海顺,张 梦.英国短缺药品联络人报告制度对我国的启示[J].卫生经济研究,2016,(12):22.
[3]丁锦希,钭江苑,李 伟.英国创新药品价格协议研究[J].卫生经济研究,2017,(05):40.
[4]李 菲.治理视域下政府对医院投入机制研究[J].卫生经济研究,2018,(05):21.
[5]董心月,张伶俐,邵 蓉.英国价值定价理念与药品补偿制度的衔接及启示[J].卫生经济研究,2018,(10):54.
DONG Xin-yue,ZHANG Ling-li,SHAO Rong.The Connection and Enlightenment of British Value Pricing Concept and Drug Compensation System[J].Journal Press of Health Economics Research,2018,(02):54.
[6]李 菲.DRGs在医院医疗费用支付中的应用研究——基于英国、德国和美国的实证分析[J].卫生经济研究,2019,(01):32.
LI Fei.Application Research of DRGs in Hospital Medical Expense Payment——Empirical Analysis Based on the UK,Germany and the US[J].Journal Press of Health Economics Research,2019,(02):32.
[7]梁 旭.英国全科医疗改革实践与启示[J].卫生经济研究,2020,(04):54.
LIANG Xu.Practice and Enlightenment of General Medical Reform in UK[J].Journal Press of Health Economics Research,2020,(02):54.
[8]朱惠敏,李文敏.英国分级诊疗影响因素分析及启示[J].卫生经济研究,2025,42(01):52.
ZHU Huimin,LI Wenmin.Analysis of Factors Influencing Graded Diagnosis and Treatment in the UK and Its Implications[J].Journal Press of Health Economics Research,2025,42(02):52.